title: [Clinical Analysis of 58 Patients with Small Cell Lung Cancer  Combined with Squamous Cell Cancer].
abstract: BACKGROUND
  Small cell lung cancer combined with squamous cell carcinoma are rare. The aim of this study was to analyze the clinicopathological characteristics and treatment, and explored the prognostic factors of this disease.
  
  
  METHODS
  Between January 2004 and December 2012, 58 patients with cytopathologically confirmed small cell lung cancers combined with squamous cell carcinoma were retrospectively analyzed. Kaplan-Meier methods were used to calculate the survival rate, and Log-rank test was used to examine differences between arms. The Cox regression model was used to analyze the independent factors affecting the overall survival (OS).
  
  
  RESULTS
  The OS of the 58 patients was 22.7 months with a range of 0.3 to 124.3 months. In univariate analysis, Karnofsky performance score before treatment, extensive disease, tumor stage were the considered prognostic factors affecting the OS rate (P<0.05). Cox multivariate analysis showed that only the tumor-node-metastasis (TNM) stage was the independent prognostic factor (P=0.019). The majority of the patients received multimodality therapy and chemotherapy was the main treatment. Distant metastasis was the main reasonfor the treatment failure.
  
  
  CONCLUSIONS
  Combined therapy with chemotherapy as the main treatment should be adopted in therapeutic regimen of the patients with small cell lung cancers combined with squamous cell carcinoma. TNM stage was the independent prognostic factor influencing the OS. .
authors.affiliation: Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Luo
authors.affiliation: Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Men
authors.affiliation: Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Zhouguang
authors.initials: Z
authors.lastname: Hui
authors.affiliation: Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Junling
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Xuezhi
authors.initials: X
authors.lastname: Hao
authors.affiliation: Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Puyuan
authors.initials: P
authors.lastname: Xing
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D015996:Survival Rate